Squamous carcinoma of the head and neck: the untreated patient

Stell, P. M.; Morton, Randall P.; Singh, S. D.

doi:10.1111/j.1365-2273.1983.tb01665.x

Cited by 10 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Die durchschnittlich zu erwartende Überlebenszeit dieser Patienten läge bei etwa 11 Monaten [26]. Die durchschnittlich zu erwartende Überlebenszeit dieser Patienten läge bei etwa 11 Monaten [26].…”

Section: Hno 2·98unclassified

Hyperfraktionierte-akzelerierte simultane Radio-Chemo-Therapie bei fortgeschrittenen Hypopharynxkarzinomen

Schrader

Schipper

Jahnke

et al. 1998

HNO

View full text Add to dashboard Cite

Forty-one patients with locally advanced hypopharyngeal carcinomas were followed for at least 3 years (median, 60 months) after simultaneous radiochemotherapy. Conventionally fractionated radiotherapy was administered as 5 x 2 Gy/week to a total dose of 30 Gy within 3 weeks. From the fourth week an accelerated hyperfractionated schedule was used as 2 x 1.4 Gy/day five days weekly given exclusively to the first order target volume of macroscopic tumor (adding up to a total dose of 72 Gy in six weeks). The second and third order target volumes received conventional fractionation only to 60 Gy and 50 Gy, respectively. The moderate acceleration of the concomitant boost scheme in the second half was counterbalanced during the first week by the introduction of a 5-fluorouracil bolus of 350 mg/M2 with 200 mg/M2 folinic acid and a subsequent continuous infusion using the same dose each 24 h for 5 days. Additionally, a Mitomycin-C bolus of 10 mg/M2 was infused at the fifth day and on the first day of the sixth week. Six weeks after treatment the patients were restaged. In cases with residual carcinoma salvage surgery was performed (11 patients). Late effects of therapy were analyzed according to the Lent-Soma index and life quality according to the European Organisation for Research and Treatment of Cancer-Module. Late effects of treatment were tolerable and were controlled locally. The 3-year-survival rate was 39%, with a local-regional recurrence-free control rate of 71%. Fifty-two percent of all cases of death were caused by distant metastases, secondary carcinomas or other diseases not related to tumor recurrence. The poor prognosis of hypopharyngeal carcinomas despite acceptable local tumor control may be due to specific biological factors present in affected patients.

show abstract

Section: Hno 2·98unclassified

Hyperfraktionierte-akzelerierte simultane Radio-Chemo-Therapie bei fortgeschrittenen Hypopharynxkarzinomen

Schrader

Schipper

Jahnke

et al. 1998

HNO

View full text Add to dashboard Cite

show abstract

“…Expected survival is the sum of survival threshold as stated by the patients and median survival with best supportive care as reported in the literature. Studies suggest a median survival with best supportive care of eight months for CRC patients and of four months for non-CRC patients [21-24]. …”

Section: Methodsmentioning

confidence: 99%

Patients’ perspectives on palliative chemotherapy of colorectal and non - colorectal cancer: a prospective study in a chemotherapy- experienced population

et al. 2013

View full text Add to dashboard Cite

BackgroundA better understanding of patients’ views on the benefit and burden obtained from palliative chemotherapy would facilitate shared decision making. We evaluated palliative cancer patients’ reported outcomes (PROs) for toxicity and investigated the survival threshold for which they would repeat chemotherapy (CTx).MethodsPatients who had received a minimum of three months of palliative CTx for advanced colorectal (CRC) or non-colorectal (non-CRC: upper gastrointestinal, lung and head-and-neck) cancer were assessed by questionnaire. Patients were questioned about PROs for toxicity, subjective burden from side effects, and were asked for the survival threshold necessary for them to repeat CTx. Expected survival (sum of indicated survival threshold and median survival time with best supportive care) was compared to the patients’ actual survival.ResultsOne hundred and thirty-four patients (CRC: 58; non-CRC: 76) were surveyed. The most frequent PRO- grade 3/4 toxicities were acne (12.8%), fatigue (9.0%), and diarrhea (8.5%). The symptom causing the highest subjective burden was fatigue and was worse than expected in 29.9% of the patients. The median survival threshold for which patients would repeat CTx was significantly longer in CRC than in non-CRC patients (p=0.01). Median expected survival was significantly longer than actual median survival (CRC: 44.0 months [22.0-65.9] compared with 30.0 months of actual survival [20.9-39.1]; non-CRC: 22.0 months [15.3-28.6] compared with 19.0 months of actual survival [15.1-22.9], p=0.03).ConclusionFatigue deserves more attention when toxicity of treatment and symptoms of disease are explained to patients. Patients’ survival expectations from palliative chemotherapy are higher than previously described, exceed the median survival time known from phase III trials, and are significantly longer than their actual survival.

show abstract

Knowledge-Based Decision Support for Laryngeal Tumour Diseases: Design and Structure of the Esther System

Haux

Höfener²,

Ingenerf³

et al. 1988

Expert Systems and Decision Support in Medicine

View full text Add to dashboard Cite

Squamous carcinoma of the head and neck: the untreated patient

Cited by 10 publications

References 24 publications

Hyperfraktionierte-akzelerierte simultane Radio-Chemo-Therapie bei fortgeschrittenen Hypopharynxkarzinomen

Hyperfraktionierte-akzelerierte simultane Radio-Chemo-Therapie bei fortgeschrittenen Hypopharynxkarzinomen

Patients’ perspectives on palliative chemotherapy of colorectal and non - colorectal cancer: a prospective study in a chemotherapy- experienced population

Knowledge-Based Decision Support for Laryngeal Tumour Diseases: Design and Structure of the Esther System

Contact Info

Product

Resources

About